Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Has Consensus Target Price of $220.00 According to Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been given a consensus recommendation of “Hold” by the eight brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $220.00.

A number of brokerages have weighed in on JSPR. Piper Sandler began coverage on Jasper Therapeutics in a report on Wednesday, August 12th. They issued an “overweight” rating and a $60.00 target price on the stock. Wall Street Zen upgraded Jasper Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. HC Wainwright reissued a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. Finally, William Blair assumed coverage on Jasper Therapeutics in a research note on Wednesday, October 14th. They issued an “outperform” rating on the stock.

Jasper Therapeutics Trading Down 2.9%

Shares of Jasper Therapeutics stock opened at $16.37 on Friday. The company has a market cap of $544.79 million, a PE ratio of -0.34 and a beta of 3.30. The company has a 50 day moving average of $17.34 and a 200-day moving average of $24.81. Jasper Therapeutics has a 1-year low of $9.45 and a 1-year high of $72.60.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings data on Friday, August 14th. The company reported ($3.00) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($8.03) by $5.03. Research analysts forecast that Jasper Therapeutics will post -28.23 earnings per share for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing therapies that target c-Kit (CD117), a protein found on hematopoietic stem cells and mast cells. The company is pursuing treatments intended to address diseases involving abnormal immune or blood-cell activity, as well as approaches that may improve preparation for hematopoietic stem-cell transplantation.

Jasper’s lead investigational product is briquilimab, formerly known as JSP191. Briquilimab is an anti-CD117 monoclonal antibody designed to deplete certain stem cells and mast cells.